{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:47:51Z","timestamp":1792226871974,"version":"4.4.0"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the\n                    <jats:italic>PHEX<\/jats:italic>\n                    gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidisciplinary group of Belgian experts convened to discuss translation of international best available evidence into locally feasible consensus recommendations. Patients with XLH may present to a wide array of primary, secondary and tertiary care physicians, among whom awareness of the disease should be raised. XLH has a very broad differential-diagnosis for which clinical features, biochemical and genetic testing in centers of expertise are recommended. Optimal care requires a multidisciplinary approach, guided by an expert in metabolic bone diseases and involving (according to the individual patient\u2019s needs) pediatric and adult medical specialties and paramedical caregivers, including but not limited to general practitioners, dentists, radiologists and orthopedic surgeons. In children with severe or refractory symptoms, FGF23 inhibition using burosumab may provide superior outcomes compared to conventional medical therapy with phosphate supplements and active vitamin D analogues. Burosumab has also demonstrated promising results in adults on certain clinical outcomes such as pseudofractures. In summary, this work outlines recommendations for clinicians and policymakers, with a vision for improving the diagnostic and therapeutic landscape for XLH patients in Belgium.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2021.641543","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T12:48:10Z","timestamp":1616158090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium"],"prefix":"10.3389","volume":"12","author":[{"given":"Micha\u00ebl R.","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"De Schepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Trouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Godefroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Boros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Heinrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bravenboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Velkeniers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Harvengt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Kaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Lombet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Verroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"van Hoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Levtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vande Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"key":"B3","unstructured":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and Mortality of Individuals With X-LinkedHypophosphatemia: A United Kingdom Real-World Data Analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J ClinEndocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B6","unstructured":"Vlaams Agentschap Zorg en GezondheidOprichting Vlaams Netwerk Zeldzame Ziekten2017"},{"key":"B7","doi-asserted-by":"publisher","first-page":"153865","DOI":"10.1016\/j.metabol.2019.01.006","article-title":"Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting","author":"Bacchetta","year":"2020","journal-title":"Metabolism"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate","article-title":"FGF23 and Associated Disorders of Phosphate Wasting","volume":"17","author":"Gohil","year":"2019","journal-title":"Pediatr Endocrinol Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.gaitpost.2020.07.007","article-title":"Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia","volume":"81","author":"Mindler","year":"2020","journal-title":"Gait Posture"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4146","article-title":"The muscle-bone relationship in X-linked hypophosphatemic rickets","volume":"98","author":"Veilleux","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1336","article-title":"Abnormalities in muscle density and muscle function in hypophosphatemic rickets","volume":"97","author":"Veilleux","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linkedhypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01193-0","article-title":"Exploring the Burden of X-Linked Hypophosphataemia: An OpportunisticQualitative Study of Patient Statements Generated During a Technology Appraisal","volume":"37","author":"Ferizovic","year":"2020","journal-title":"Adv Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"key":"B16","first-page":"33","article-title":"Clinical course of hypophosphatemic rickets in 23 adults","volume":"45","author":"Berndt","year":"1996","journal-title":"Clin Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemiaand skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"154049","DOI":"10.1016\/j.metabol.2019.154049","article-title":"Management of X-linked hypophosphatemia in adults","author":"Lecoq","year":"2020","journal-title":"Metabolism"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00365","article-title":"The Lifelong Impact of X-Linked Hypophosphatemia: Results From aBurden of Disease Survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.17294\/2330-0698.1727","article-title":"Giving Credence to the Experience of X-Linked Hypophosphatemia inAdulthood: An Interprofessional Mixed-Methods Study","volume":"7","author":"Hughes","year":"2020","journal-title":"J Patient Cent ResRev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.8.4181","article-title":"Cardiovascular abnormalities in patients with X-linkedhypophosphatemia","volume":"82","author":"Nehgme","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets\u2013role of secondaryhyperparathyroidism","volume":"18","author":"Alon","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0481","article-title":"Increased prevalence of overweight and obesity in children withX-linked hypophosphatemia","volume":"9","author":"Zhukouskaya","year":"2020","journal-title":"Endocr Connect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa859","article-title":"Higher prevalence of non-skeletal comorbidity related to X-linkedhypophosphataemia: a UK parallel cohort study using CPRD","author":"Hawley","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and managementof X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH inchildren and adolescents: British paediatric and adolescent bone grouprecommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa495","article-title":"Growth Curves for Children with X-linkedHypophosphatemia","volume":"105","author":"Mao","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/000456329002700312","article-title":"Pseudohypophosphataemia as a result of bilirubin interference","volume":"27","author":"Duncanson","year":"1990","journal-title":"Ann Clin Biochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and Approaches to Phosphate and Fibroblast Growth Factor23 Reduction in CKD","volume":"26","author":"Isakova","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of Iron Isomaltoside vs Ferric Carboxymaltose onHypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","article-title":"Hypophosphatemia: the common denominator of allrickets","volume":"27","author":"Tiosano","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502249102","article-title":"Hypophosphatemia leads to rickets by impairing caspase-mediatedapoptosis of hypertrophic chondrocytes","volume":"102","author":"Sabbagh","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","article-title":"Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia","volume":"97","author":"Seikaly","year":"1996","journal-title":"Pediatrics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05622-7","article-title":"A unique case of light chain (AL) amyloidosis masquerading ashypophosphatemic osteomalacia","volume":"32","author":"Malhotra","year":"2021","journal-title":"Osteoporos Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz260","article-title":"Mutation of SGK3, a Novel Regulator of Renal Phosphate Transport,Causes Autosomal Dominant Hypophosphatemic Rickets","volume":"105","author":"Cebeci","year":"2020","journal-title":"J Clin EndocrinolMetab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-11-0523","article-title":"Increased circulating levels of FGF23: an adaptive response inprimary hyperparathyroidism","volume":"166","author":"Witteveen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.06.057","article-title":"FGF23, metabolic risk factors, and blood pressure in patients withprimary hyperparathyroidism undergoing parathyroid adenomectomy","volume":"159","author":"Nilsson","year":"2016","journal-title":"Surgery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070783","article-title":"Parathyroid hormone regulates fibroblast growth factor-23 in a mousemodel of primary hyperparathyroidism","volume":"18","author":"Kawata","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98680","article-title":"CYP3A4 mutation causes vitamin D-dependent rickets type3","volume":"128","author":"Roizen","year":"2018","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jbmr.1740","article-title":"Fibroblast growth factor 23 inhibits extrarenal synthesis of1,25-dihydroxyvitamin D in human monocytes","volume":"28","author":"Bacchetta","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81928","article-title":"CYP24 inhibition as a therapeutic target in FGF23-mediated renalphosphate wasting disorders","volume":"126","author":"Bai","year":"2016","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in Patients With X-LinkedHypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linkedhypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00332","article-title":"Progression of Mineral Ion Abnormalities in Patients With JansenMetaphyseal Chondrodysplasia","volume":"103","author":"Saito","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00597-y","article-title":"Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of theLiterature","volume":"105","author":"Liu","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominanthypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemicrickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2013.12.001","article-title":"Iron and fibroblast growth factor 23 in X-linked hypophosphatemia","volume":"60","author":"Imel","year":"2014","journal-title":"Bone"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2391","article-title":"Iron Supplementation Associated With Loss of Phenotype in Autosomal Dominant Hypophosphatemic Rickets","volume":"100","author":"Kapelari","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3878","article-title":"Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-inducedhypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-014-9854-7","article-title":"Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia","volume":"94","author":"Saeedi","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.06.029","article-title":"A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene","volume":"49","author":"Saito","year":"2011","journal-title":"Bone"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00082","article-title":"Disrupted Protein Expression and Altered Proteolytic Events in Hypophosphatemic Dentin Can Be Rescued by Dentin Matrix Protein 1","volume":"11","author":"Guirado","year":"2020","journal-title":"Front Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3938","article-title":"Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations","volume":"35","author":"Kotwal","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3911","article-title":"Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency","volume":"35","author":"Oheim","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41436-020-00983-0","article-title":"Prospective phenotyping of long-term survivors of generalizedarterial calcification of infancy (GACI)","volume":"23","author":"Ferreira","year":"2021","journal-title":"Genet Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1159\/000354661","article-title":"Hearing loss is part of the clinical picture of ENPP1 loss of function mutation","volume":"81","author":"Brachet","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61334","article-title":"Novel homozygous ENPP1 mutation causes generalized arterial calcifications of infancy, thrombocytopenia, and cardiovascular and central nervous system syndrome","volume":"179","author":"Staretz-Chacham","year":"2019","journal-title":"Am J Med Genet A"},{"key":"B61","doi-asserted-by":"publisher","first-page":"115190","DOI":"10.1016\/j.bone.2019.115190","article-title":"Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy","volume":"132","author":"Whyte","year":"2020","journal-title":"Bone"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712361105","article-title":"A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism","volume":"105","author":"Brownstein","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402218111","article-title":"Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis","volume":"111","author":"Tagliabracci","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0444-x","article-title":"Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3","volume":"16","author":"de Las Rivas","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815166116","article-title":"Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation","volume":"116","author":"Takashi","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bone.2014.06.026","article-title":"Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome","volume":"67","author":"Takeyari","year":"2014","journal-title":"Bone"},{"key":"B67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12881-015-0154-5","article-title":"Variability of systemic and oro-dental phenotype in two families with non-lethal Raine syndrome with FAM20C mutations","volume":"16","author":"Acevedo","year":"2015","journal-title":"BMC Med Genet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4667-6","article-title":"A novel FAM20C mutation causing hypophosphatemic osteomalacia withosteosclerosis (mild Raine syndrome) in an elderly man with spontaneous osteonecrosis of theknee","volume":"30","author":"Rolvien","year":"2019","journal-title":"Osteoporos Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3034","article-title":"Raine Syndrome (OMIM #259775), Caused By FAM20C Mutation, IsCongenital Sclerosing Osteomalacia With Cerebral Calcification (OMIM 259660)","volume":"32","author":"Whyte","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122004","article-title":"Autoimmune hyperphosphatemic tumoral calcinosis in a patient withFGF23 autoantibodies","volume":"128","author":"Roberts","year":"2018","journal-title":"J Clin Invest"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e10185","DOI":"10.1002\/jbm4.10185","article-title":"Hyperphosphatemic Familial Tumoral Calcinosis With Galnt3 Mutation:Transient Response to Anti-Interleukin-1 Treatments","volume":"3","author":"Dauchez","year":"2019","journal-title":"JBMR Plus"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onsethypophosphatemic osteomalacia in China: Report of 39 cases and review of theliterature","volume":"27","author":"Jiang","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-011-0290-8","article-title":"Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia","volume":"30","author":"Imanishi","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32395","article-title":"Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome","author":"Hoffman","year":"2008","journal-title":"Am J Med Genet A"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1602816","article-title":"Osteoglophonic Dysplasia: Phenotypic and Radiological Clues","volume":"6","author":"Kuthiroly","year":"2017","journal-title":"J Pediatr Genet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1515\/JPEM.2007.20.1.79","article-title":"Hypophosphatemic rickets in opsismodysplasia","volume":"20","author":"Zeger","year":"2007","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B77","doi-asserted-by":"crossref","DOI":"10.1002\/9781119266594.ch89","article-title":"Rickets and Osteomalacia","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"Laurent","year":"2018"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.4.648","article-title":"Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma","volume":"39","author":"Rosalki","year":"1993","journal-title":"Clin Chem"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/42.12.1970","article-title":"Immunoadsorption assay for bone alkaline phosphatase compared with wheat germ agglutinin precipitation assay in serum from (pre)pubertal girls","volume":"42","author":"Bouman","year":"1996","journal-title":"Clin Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphateconcentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/000456329803500203","article-title":"Renal tubular reabsorption of phosphate (TmP\/GFR): indications andinterpretation","volume":"35","author":"Payne","year":"1998","journal-title":"Ann Clin Biochem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital Conditions of Hypophosphatemia inChildren","volume":"108","author":"Imel","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00746.x","article-title":"Twenty-four-hour urine chemistries and the risk of kidney stonesamong women and men","volume":"59","author":"Curhan","year":"2001","journal-title":"Kidney Int"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.227","article-title":"Defining hypercalciuria in nephrolithiasis","volume":"80","author":"Pak","year":"2011","journal-title":"Kidney Int"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s004670000510","article-title":"Normal urinary calcium\/creatinine ratios in African-American andCaucasian children","volume":"16","author":"So","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1258\/00045630677852010","article-title":"Determining urinary calcium\/creatinine cut-offs for the paediatricpopulation using published data","volume":"43","author":"Metz","year":"2006","journal-title":"Ann Clin Biochem"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-84800-362-0_55","article-title":"Metabolic Investigations: When and in Whom","volume-title":"Urinary Tract Stone Disease","author":"Goldfarb","year":"2010"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2017-0767","article-title":"Pediatric reference intervals for 1,25-dihydroxyvitamin D using theDiaSorin LIAISON XL assay in the healthy CALIPER cohort","volume":"56","author":"Higgins","year":"2018","journal-title":"Clin Chem LabMed"},{"key":"B89","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1210\/jc.2012-2772","article-title":"Active vitamin D (1,25-dihydroxyvitamin D) and bone health inmiddle-aged and elderly men: the European Male Aging Study (EMAS)","volume":"98","author":"Vanderschueren","year":"2013","journal-title":"J ClinEndocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor 23","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.02.032","article-title":"Pre-analytical stability of FGF23 with the contemporary immunoassays","volume":"493","author":"Dirks","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3543-5","article-title":"Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type","volume":"27","author":"El-Maouche","year":"2016","journal-title":"Osteoporos Int"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a New Fully Automated Assay for Plasma Intact FGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0460","article-title":"FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference","volume":"58","author":"Piketty","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05362-8","article-title":"European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism","volume":"31","author":"Cavalier","year":"2020","journal-title":"Osteoporos Int"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11832-016-0713-0","article-title":"EOS((R)) biplanar X-ray imaging: concept, developments, benefits, and limitations","volume":"10","author":"Melhem","year":"2016","journal-title":"J Child Orthop"},{"key":"B98","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","article-title":"Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score","volume":"122","author":"Thacher","year":"2019","journal-title":"Bone"},{"key":"B99","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00003072-199606000-00013","article-title":"Whole-body bone scan findings in X-linked hypophosphatemia","volume":"21","author":"Van de Wiele","year":"1996","journal-title":"Clin Nucl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00355","article-title":"Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH)","volume":"11","author":"Raimann","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.04.016","article-title":"68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT","volume":"64","author":"Breer","year":"2014","journal-title":"Bone"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2052","article-title":"(68)Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.11.8923863","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.01.021","article-title":"Clinical and genetic analysis in a large Chinese cohort of patientswith X-linked hypophosphatemia","volume":"121","author":"Zhang","year":"2019","journal-title":"Bone"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-013-9736-4","article-title":"Dosage effect of a Phex mutation in a murine model of X-linkedhypophosphatemia","volume":"93","author":"Ichikawa","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused byPHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.20572","article-title":"Anthropometric characteristics of X-linkedhypophosphatemia","author":"Pronicka","year":"2004","journal-title":"Am J Med Genet A"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets inadults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.34242","article-title":"Craniofacial morphology in patients with hypophosphatemic rickets: a cephalometric study focusing on differences between bone of cartilaginous and intramembranous origin","author":"Gjorup","year":"2011","journal-title":"Am J Med Genet A"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.06.002","article-title":"Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets","volume":"43","author":"Ichikawa","year":"2008","journal-title":"Bone"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2307","article-title":"PHEX 3\u2019-UTR c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets","volume":"30","author":"Mumm","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3955","article-title":"X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3\u2019-UTR Mutation c.*231A>G (A Retrospective Case-Control Study)","volume":"35","author":"Smith","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4035","article-title":"Functional Characterization of PHEX Gene Variants in Children With X-Linked Hypophosphatemic Rickets Shows No Evidence of Genotype-Phenotype Correlation","volume":"35","author":"Zheng","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2012.56","article-title":"Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets","volume":"57","author":"Beck-Nielsen","year":"2012","journal-title":"J Hum Genet"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.05.040","article-title":"Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets","volume":"79","author":"Capelli","year":"2015","journal-title":"Bone"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7730","article-title":"X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene","volume":"86","author":"Christie","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B119","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1530\/EJE-20-0275","article-title":"Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting","volume":"183","author":"Thiele","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01240-6","article-title":"Novel variants and uncommon cases among southern Chinese children with X-linked hypophosphatemia","volume":"43","author":"Lin","year":"2020","journal-title":"J\u00a0Endocrinol Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03919.x","article-title":"Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets","volume":"74","author":"Ruppe","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0071","article-title":"Mutational analysis of patients with FGF23-related hypophosphatemic rickets","volume":"167","author":"Kinoshita","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-019-00732-2","article-title":"Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives","volume":"170","author":"Raimann","year":"2020","journal-title":"Wien Med Wochenschr"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.apmr.2017.07.015","article-title":"Effectiveness of Exercise Programs in Ankylosing Spondylitis: A Meta-Analysis of Randomized Controlled Trials","volume":"99","author":"Pecourneau","year":"2018","journal-title":"Arch Phys Med Rehabil"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.08.003","article-title":"Exercise for ankylosing spondylitis: An evidence-based consensus statement","volume":"45","author":"Millner","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213585","article-title":"2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis","volume":"77","author":"Rausch Osthoff","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e1798","DOI":"10.1210\/clinem\/dgaa064","article-title":"Osteoarthritis, Osteophytes, and Enthesophytes Affect BiomechanicalFunction in Adults With X-linked Hypophosphatemia","volume":"105","author":"Steele","year":"2020","journal-title":"J Clin EndocrinolMetab"},{"key":"B129","article-title":"Voor welke zware aandoeningen geniet uw pati\u00ebnt van een voorkeurstarief voor zijn kinesitherapie behandeling","year":"2020"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318175d788","article-title":"Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets","volume":"64","author":"Seikaly","year":"2008","journal-title":"Pediatr Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2006.01326.x","article-title":"Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment","volume":"13","author":"Chaussain-Miller","year":"2007","journal-title":"Oral Dis"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1177\/0022034516677528","article-title":"Phosphate and Vitamin D Prevent Periodontitis in X-Linked Hypophosphatemia","volume":"96","author":"Biosse Duplan","year":"2017","journal-title":"J Dent Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.75.3.1517380","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B137","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1297\/cpe.18.29","article-title":"Patients with Hypophosphatemic Osteomalacia Need Continuous Treatment during Adulthood","volume":"18","author":"Suzuki","year":"2009","journal-title":"Clin Pediatr Endocrinol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111900","article-title":"Healing of bone disease in X-linked hypophosphatemic rickets\/osteomalacia. Induction and maintenance with phosphorus and calcitriol","volume":"75","author":"Harrell","year":"1985","journal-title":"J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-3-463","article-title":"X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization","volume":"52","author":"Costa","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00186","article-title":"1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice","volume":"160","author":"Martins","year":"2019","journal-title":"Endocrinology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2783","article-title":"1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression","volume":"31","author":"Liu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115767","article-title":"Vitamin D supplementation improves bone mineralisation independent of dietary phosphate in male X-linked hypophosphatemic (Hyp) mice","volume":"115767","author":"Barratt","year":"2020","journal-title":"Bone"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198911000-00002","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid","year":"1989","journal-title":"Med (Baltimore)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM197906143002415","article-title":"Hypophosphatemic rickets and breast milk","volume":"300","author":"Reade","year":"1979","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-198905000-00021","article-title":"Low breast milk phosphorus concentration in familial hypophosphatemia","volume":"8","author":"Jonas","year":"1989","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-2061","article-title":"Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization","volume":"155","author":"Ma","year":"2014","journal-title":"Endocrinology"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/BF02405118","article-title":"Normal milk composition in lactating X-linked hypophosphatemic mice despite continued hypophosphatemia","volume":"35","author":"Delzer","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia","author":"Padidela","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0399","article-title":"Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion","volume":"96","author":"Zivicnjak","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.108955","article-title":"Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets","volume":"138","author":"Baroncelli","year":"2001","journal-title":"J Pediatr"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1159\/000113021","article-title":"Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets","volume":"69","author":"M\u00e4kitie","year":"2008","journal-title":"Horm Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3820-3","article-title":"Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets","volume":"33","author":"Meyerhoff","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2017.08.001","article-title":"Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)","volume":"36","author":"Rothenbuhler","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"B164","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","article-title":"Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density","volume":"127","author":"Saggese","year":"1995","journal-title":"J Pediatr"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0383","article-title":"A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet","volume":"159","author":"Raeder","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1542\/peds.108.1.e6","article-title":"Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia","volume":"108","author":"Seikaly","year":"2001","journal-title":"Pediatrics"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s004670000425","article-title":"Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia","volume":"15","author":"Seikaly","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jbmr.3923","article-title":"Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice","volume":"35","author":"Carpenter","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4101","article-title":"Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice PartiallyRescues the Deficient Mineralization Without Correcting Hypophosphatemia","volume":"35","author":"Hoac","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"107556","DOI":"10.1016\/j.jsb.2020.107556","article-title":"Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH)","volume":"211","author":"Fratzl-Zelman","year":"2020","journal-title":"J Struct Biol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"e10374","DOI":"10.1002\/jbm4.10374","article-title":"Bisphosphonate-Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome","volume":"4","author":"Cundy","year":"2020","journal-title":"JBMR Plus"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e18425","DOI":"10.1097\/MD.0000000000018425","article-title":"Rotational and translational osteotomy for treatment of severe deformity in hypophosphatemic rickets: A case report","volume":"99","author":"Li","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-14-00082","article-title":"Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets","volume":"23","author":"Sharkey","year":"2015","journal-title":"J Am Acad Orthop Surg"},{"key":"B175","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1302\/1863-2548.11.170003","article-title":"The orthopaedic management of lower limb deformity in hypophosphataemic rickets","volume":"11","author":"Horn","year":"2017","journal-title":"J Child Orthop"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-015-2814-7","article-title":"Results of deformity correction in children with X-linked hereditary hypophosphatemic rickets by external fixation or combined technique","volume":"39","author":"Popkov","year":"2015","journal-title":"Int Orthop"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0154","article-title":"Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR)","volume":"6","author":"Gizard","year":"2017","journal-title":"Endocr Connect"},{"key":"B178","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3171\/2015.10.PEDS15273","article-title":"Hypophosphatemic rickets and craniosynostosis: a multicenter case series","volume":"17","author":"Vega","year":"2016","journal-title":"J Neurosurg Pediatr"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3614","article-title":"High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200207000-00038","article-title":"Cervical spinal cord compression attributable to a calcified intervertebral disc in a patient with X-linked hypophosphatemic rickets: case report and review of the literature","volume":"51","author":"Soehle","year":"2002","journal-title":"Neurosurgery"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.4184\/asj.2015.9.1.106","article-title":"Cervical ossification of posterior longitudinal ligament in x-linked hypophosphatemic rickets revealing homogeneously increased vertebral bone density","volume":"9","author":"Shiba","year":"2015","journal-title":"Asian Spine J"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2016.07.076","article-title":"Minimally Invasive Surgical Management of Thoracic Ossification of the Ligamentum Flavum Associated with X-linked Hypophosphatemia","volume":"94","author":"Riccio","year":"2016","journal-title":"World Neurosurg"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003237","article-title":"Ultra-early onset of ossification of the posterior longitudinal ligament with congenital rickets","volume":"87","author":"Nakagawa","year":"2016","journal-title":"Neurology"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"M\u00e4kitie","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.139.2.218","article-title":"Parathyroidectomy for tertiary hyperparathyroidism associated withX-linked dominant hypophosphatemic rickets","volume":"139","author":"Savio","year":"2004","journal-title":"Arch Surg"},{"key":"B186","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-020-01398-5","article-title":"Rare musculoskeletal diseases in adults: a research priority settingpartnership with the James Lind Alliance","volume":"15","author":"Mickute","year":"2020","journal-title":"Orphanet J Rare Dis"}],"updated-by":[{"DOI":"10.3389\/fendo.2021.686401","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.641543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T11:29:28Z","timestamp":1621942168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.641543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":186,"alternative-id":["10.3389\/fendo.2021.641543"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.641543","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"article-number":"641543"}}